BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu J, Chen GG, Lai PBS. Targeting hepatocyte growth factor/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies. Med Res Rev 2021;41:507-24. [PMID: 33026703 DOI: 10.1002/med.21738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Xiao X, Wang J, Wang Y, Yu Y. Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma. Biochem Genet 2022. [PMID: 35723810 DOI: 10.1007/s10528-022-10239-y] [Reference Citation Analysis]
2 Nag A, Dhull N, Gupta A. Evaluation of tea (Camellia sinensis L.) phytochemicals as multi-disease modulators, a multidimensional in silico strategy with the combinations of network pharmacology, pharmacophore analysis, statistics and molecular docking. Mol Divers 2022. [PMID: 35536529 DOI: 10.1007/s11030-022-10437-1] [Reference Citation Analysis]
3 Guo Y, Ren Y, Dong X, Kan X, Zheng C. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. JHC 2022;Volume 9:343-55. [DOI: 10.2147/jhc.s358539] [Reference Citation Analysis]
4 Yuan HH, Zhang XC, Wei XL, Zhang WJ, Du XX, Huang P, Chen H, Bai L, Zhang HF, Han Y. LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways. J Cancer 2022;13:253-67. [PMID: 34976187 DOI: 10.7150/jca.65687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol 2021;12:731527. [PMID: 34804015 DOI: 10.3389/fimmu.2021.731527] [Reference Citation Analysis]
6 Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang D, Yang J, Zhang Q, Wang G, Zhang Z, Zhang Y, Li J. Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors. Eur J Med Chem 2021;223:113648. [PMID: 34175535 DOI: 10.1016/j.ejmech.2021.113648] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762. Front Pharmacol 2021;12:678620. [PMID: 34012402 DOI: 10.3389/fphar.2021.678620] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells 2021;10:123. [PMID: 33440657 DOI: 10.3390/cells10010123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yu J, Xia X, Dong Y, Gong Z, Li G, Chen GG, Lai PBS. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling. Theranostics 2021;11:2123-36. [PMID: 33500715 DOI: 10.7150/thno.49368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]